Log in

ELMD Electromed, Inc. NYSE · United States

Electromed (ELMD) news

Electromed, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker ELMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Electromed news

We have not published a story on Electromed yet. When there is news, it will appear here.

What Electromed does

Electromed, Inc. develops, manufactures, markets and sells airway clearance therapy, led by the SmartVest Airway Clearance System, which delivers high frequency chest wall oscillation (HFCWO) to patients with compromised pulmonary function. The company primarily uses a direct-to-patient and provider model. It obtains referrals from clinicians, manages insurance claims for patients, delivers the system to their homes and trains them on its use. It also sells into the acute care setting for patients after surgery, in intensive care, or admitted for a lung infection. Since 2000 it has marketed SmartVest and its predecessor products to patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. The FDA has cleared the SmartVest System to promote airway clearance and improve bronchial drainage, and the system is available only with a physician prescription. The company was incorporated in Minnesota in 1992 and is listed on the NYSE American under the ticker ELMD.

Product or programWhat it isStage
SmartVest ClearwayNext generation HFCWO airway clearance system with inflatable garment and programmable generatorFDA cleared; available only with a physician prescription
SmartVest SQLHFCWO airway clearance model sold into homecare and hospital marketsCurrently available

Summarised from the company's 10-K filed Aug 25, 2026.

Electromed annual financials

LineFY ended Jun 30, 2026FY ended Jun 30, 2025
Research and development$1.3 million$996,000
Net income (loss)$11.3 million$7.5 million
Cash from operations$9.7 million$11.4 million
Cash and equivalents$20.4 million$15.3 million

Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $20.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Electromed

What is the ticker symbol of Electromed?

Electromed, Inc. trades under the ticker ELMD on NYSE.

Where is Electromed listed?

Electromed, Inc. is listed on NYSE.

Which country or territory is Electromed listed under?

Our directory records Electromed, Inc. under United States.

Does aibio.space cover Electromed?

aibio.space lists Electromed, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What does Electromed develop?

Electromed, Inc. develops, manufactures, markets and sells airway clearance therapy, led by the SmartVest Airway Clearance System, which delivers high frequency chest wall oscillation (HFCWO) to patients with compromised pulmonary function. The company primarily uses a direct-to-patient and provider model.

What is SmartVest Clearway from Electromed?

SmartVest Clearway: Next generation HFCWO airway clearance system with inflatable garment and programmable generator Stage: FDA cleared; available only with a physician prescription.

What is SmartVest SQL from Electromed?

SmartVest SQL: HFCWO airway clearance model sold into homecare and hospital markets Stage: Currently available.

Is Electromed profitable?

Electromed, Inc. reported net income of $11.3 million for the fiscal year ended Jun 30, 2026, and generated $9.7 million of cash from operations, per its annual report to the SEC.

How much does Electromed spend on research and development?

$1.3 million in the fiscal year ended Jun 30, 2026, per its annual report.

How much cash does Electromed have?

$20.4 million in cash at Jun 30, 2026, per its 10-K.

Investor discussion: Electromed

Members talk about Electromed (ELMD). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NYSE:ELMD on TradingView.

Listing details

Electromed, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker ELMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Electromed, Inc.
Ticker
ELMD
Listing
NYSE
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.